Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
22,000
-900 (-3.93%)
Apr 28, 2026, 3:30 PM KST
260.66%
Market Cap 987.53B
Revenue (ttm) 53.39B
Net Income (ttm) 15.78B
Shares Out 44.89M
EPS (ttm) n/a
PE Ratio 62.57
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 395,702
Average Volume 502,105
Open 22,650
Previous Close 22,900
Day's Range 21,900 - 22,650
52-Week Range 5,000 - 28,900
Beta n/a
RSI 49.19
Earnings Date Mar 20, 2026

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.